Ohsong Pharm (CEO Kim Young-joong) established Brio Pharma, a subsidiary in Japan, and stepped up to strengthen the status of its export business.

Ohsong Pharm, an affiliate of Kunil Pharmaceutical Company and Penmax, is a joint research and product concept that helps domestic and foreign pharmaceutical pharmaceutical companies enter Japan. 

Brio Pharma, a wholly invested subsidiary of Ohsong Pharm, has an office in Tokyo, Japan, and began working on July 3.

Brio Pharma obtains the " pharmaceutical manufacturing and selling " license in Japan and performs clinical trials and applications directly. It is very rare for domestic Healthcare companies to operate licensed and clinical competent entities in Japan, from ' O.Song Farm ' and Brio Pharma, to provide clinical trial solutions to domestic companies considering their entry to Japan. 

" Brio Pharma is easy to link with local partners by having permission, " said an official at Ospam, adding that the company has significantly enhanced its export confidence and confidence with the establishment of Brio Pharma. " 

O'Song Farm has established itself for more than a decade solely by specializing in imports and exports of Japan, and O'Song Farm and Brio Pharma are Japanese pharmacists and Japanese engineers with many experience in quality. 

Meanwhile, Ohsong Pharm won $ 10 million in exports and $ 20 million in exports on Trade Day in 2010 (47 times) and in 2011 (48 times), respectively, and was awarded for export to Jeju in 2016.